Erratum: Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1-34-T>C polymorphism (Breast Cancer Research and Treatment DOI: 10.1007/s10549-009-0490-2);Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1 - -34-T>C polymorphism

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 737-744

  Abbas, Sascha ^a   Baisch, Christian ^a   Braendle, Wilhelm ^a   Brauch, Hiltrud ^a   Brors, Benedikt ^a   Brüning, Thomas ^a   Chang Claude, Jenny ^a   Dahmen, Norbert ^a   Dünnebier, Thomas ^a   Eils, Roland ^a   Flesch Janys, Dieter ^a   Hamann, Ute ^a   Hein, Rebecca ^a   Justenhoven, Christina ^a   Ko, Yon Dschun ^a   Kropp, Silke ^a   Pathimos, Margie ^a   Pesch, Beate ^a   Spickenheuer, Anne ^a   Zapatka, Marc ^a  

^a NONE

Author keywords

Breast cancer risk; Estrogen monotherapy CYP17; Polymorphisms; Steroid hormone biosynthesis

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 17A1; ESTROGEN; PROGESTERONE; STEROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HORMONAL THERAPY; HORMONE RESPONSE; HORMONE SYNTHESIS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

EID: 77950864860     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0880-5     Document Type: Erratum

References (27)

1. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A (2002) Metaanalyses of therapies for postmenopausal osteoporosis. V. Metaanalysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529-539
2. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427 (Pubitemid 36999703)
3. RossouwJE,AndersonGL,PrenticeRL,LaCroixAZ,KooperbergC,StefanickML, JacksonRD,BeresfordSA,HowardBV,JohnsonKC,KotchenJM,OckeneJ, WritingGroupfortheWomen'sHealthInitiativeInvestigators(2002) Risksandbenefitsofestrogenplusprogestininhealthypostmenopausalwomen: principalresultsFromtheWomen'sHealthInitiativerandomizedcontrolledtrial.JAMA288: 321-333(Pubitemid34761611)
4. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123: 933-941 (Pubitemid 352032424)
5. NewcombPA,Titus-ErnstoffL,EganKM,Trentham-DietzA,BaronJA,StorerBE, WillettWC,StampferMJ(2002)Postmenopausalestrogenandprogestinuseinrelation- breastcancerrisk.CancerEpidemiolBiomarkersPrev11:593-600(Pubitemid34760816)
6. RossRK,Paganini-HillA,WanPC,PikeMC(2000) Effectofhormonereplacementtherapyonbreastcancerrisk: estrogenversusestrogenplusprogestin.JNatlCancerInst92:328-332(Pubitemid30117736)
7. SchairerC,LubinJ,TroisiR,SturgeonS,BrintonL,HooverR(2000) Menopausalestrogenandestrogen-progestinreplacementtherapyandbreastcancerrisk. JAMA283:485-491(Pubitemid30062864)
8. Seeger H, Mueck AO (2008) Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109: 11-15
9. Pawlak KJ, Wiebe JP (2007) Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J Steroid Biochem Mol Biol 107:172-179 (Pubitemid 47380373)
10. Poutanen M, Isomaa V, Peltoketo H, Vihko R (1995) Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol 55:525-532 (Pubitemid 26019338)
11. Wiebe JP (2006) Progesterone metabolites in breast cancer. Endocr Relat Cancer 13: 717-738
12. Wiebe JP, Souter L, Zhang G (2006) Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol 100:129-140 (Pubitemid 44175837)
13. ZumoffB(1998) Doespostmenopausalestrogenadministrationincreasetheriskofbreastcancer? Contributionsofanimal,biochemical,andclinicalinvestigativestudies- aresolutionofthecontroversy.ProcSocExpBiolMed217:30-37(Pubitemid28023567)
14. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 24:1823-1830
15. KeyT,ApplebyP,BarnesI,ReevesG(2002) Endogenoussexhormonesandbreastcancerinpostmenopausalwomen: reanalysisofnineprospectivestudies.JNatlCancerInst94:606-616(Pubitemid34498648)
16. Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29:766-771 (Pubitemid 351494164)
17. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450cl7alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585-587
18. HaimanCA,HankinsonSE,SpiegelmanD,ColditzGA,WillettWC,SpeizerFE,KelseyKT, HunterDJ(1999) TherelationshipbetweenapolymorphisminCYP17withplasmahormonelevelsandbreastcan cer.CancerRes59:1015-1020(Pubitemid29135960)
19. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women (2009) Breast Cancer Res Treat. doi :10.1.007/s10549-009-0407-0
20. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933-941 (Pubitemid 352032424)
21. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harm V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137-149 (Pubitemid 351623246)
22. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Toloczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubinski J, Scott RJ, Hamann U (2009) BRCAl-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat
23. Yang C, Hamajima N, Iwata H, Saito T, Matsuo K, Hirose K, Inoue M, Takezaki T, Tajima K (2002) A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women. Breast Cancer Res 4:R8
24. WacholderS,ChanockS,Garcia-ClosasM,ElGL,RothmanN(2004) Assessingtheprobabilitythatapositivereportisfalse: anapproachformolecularepidemiologystudies.JNatlCancerInst96:434- 442(Pubitemid38443646)
25. Narjoz C, Marisa L, Imbeaud S, Paris A, Delacroix H, Beaune P, De Waziers I (2009) Genomic consequences of cytochrome P450 2C9 overexpression in human hepatoma cells. Chem Res Toxicol 22:779-787
26. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N (1992) Structure of human type II 5 alpha-reductase gene. Endocrinology 131: 1571-1573
27. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 13:213-219 (Pubitemid 38222551)